174 related articles for article (PubMed ID: 35616586)
1. Risk of malignant melanoma and non-melanoma skin cancer in rheumatoid arthritis patients initiating methotrexate versus hydroxychloroquine: a cohort study.
Lee H; Chen SK; Gautam N; Vine SM; He M; Desai RJ; Weinblatt ME; Glynn RJ; Kim SC
Clin Exp Rheumatol; 2023 Jan; 41(1):110-117. PubMed ID: 35616586
[TBL] [Abstract][Full Text] [Related]
2. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.
Chakravarty EF; Michaud K; Wolfe F
J Rheumatol; 2005 Nov; 32(11):2130-5. PubMed ID: 16265690
[TBL] [Abstract][Full Text] [Related]
3. Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme.
Curtis JR; Lee EB; Martin G; Mariette X; Terry KK; Chen Y; Geier J; Andrews J; Kaur M; Fan H; Nduaka CI
Clin Exp Rheumatol; 2017; 35(4):614-622. PubMed ID: 28240592
[TBL] [Abstract][Full Text] [Related]
4. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.
Kim SC; Solomon DH; Liu J; Franklin JM; Glynn RJ; Schneeweiss S
Am J Med; 2015 May; 128(5):539.e7-17. PubMed ID: 25534420
[TBL] [Abstract][Full Text] [Related]
5. The influence of disease-modifying anti-rheumatic drugs and corticosteroids on the association between rheumatoid arthritis and skin cancer: a nationwide retrospective case-control study in Taiwan.
Tseng HW; Lu LY; Lam HC; Tsai KW; Huang WC; Shiue YL
Clin Exp Rheumatol; 2018; 36(3):471-478. PubMed ID: 29303707
[TBL] [Abstract][Full Text] [Related]
6. Risk of venous thromboembolism associated with methotrexate versus hydroxychloroquine for rheumatoid arthritis: A propensity score-matched cohort study.
He M; Pawar A; Desai RJ; Glynn RJ; Lee H; Weinblatt ME; Solomon DH; Kim SC
Semin Arthritis Rheum; 2021 Dec; 51(6):1242-1250. PubMed ID: 34757241
[TBL] [Abstract][Full Text] [Related]
7. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.
Scott FI; Mamtani R; Brensinger CM; Haynes K; Chiesa-Fuxench ZC; Zhang J; Chen L; Xie F; Yun H; Osterman MT; Beukelman T; Margolis DJ; Curtis JR; Lewis JD
JAMA Dermatol; 2016 Feb; 152(2):164-72. PubMed ID: 26510126
[TBL] [Abstract][Full Text] [Related]
8. Disease-modifying anti-rheumatic drugs and non-melanoma skin cancer in inflammatory arthritis patients: a retrospective cohort study.
Lange E; Blizzard L; Venn A; Francis H; Jones G
Rheumatology (Oxford); 2016 Sep; 55(9):1594-600. PubMed ID: 27185957
[TBL] [Abstract][Full Text] [Related]
9. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
Solomon DH; Massarotti E; Garg R; Liu J; Canning C; Schneeweiss S
JAMA; 2011 Jun; 305(24):2525-31. PubMed ID: 21693740
[TBL] [Abstract][Full Text] [Related]
10. Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis.
Wang JL; Yin WJ; Zhou LY; Zhou G; Liu K; Hu C; Zuo XC; Wang YF
Clin Rheumatol; 2020 Mar; 39(3):769-778. PubMed ID: 31823140
[TBL] [Abstract][Full Text] [Related]
11. Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis.
Amari W; Zeringue AL; McDonald JR; Caplan L; Eisen SA; Ranganathan P
Rheumatology (Oxford); 2011 Aug; 50(8):1431-9. PubMed ID: 21415022
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Risks of Hydroxychloroquine vs Methotrexate in Patients With Rheumatoid Arthritis.
D'Andrea E; Desai RJ; He M; Glynn RJ; Lee H; Weinblatt ME; Kim SC
J Am Coll Cardiol; 2022 Jul; 80(1):36-46. PubMed ID: 35772915
[TBL] [Abstract][Full Text] [Related]
13. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis.
Ozen G; Pedro S; Holmqvist ME; Avery M; Wolfe F; Michaud K
Ann Rheum Dis; 2017 May; 76(5):848-854. PubMed ID: 27836820
[TBL] [Abstract][Full Text] [Related]
14. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register.
Mercer LK; Green AC; Galloway JB; Davies R; Lunt M; Dixon WG; Watson KD; ; Symmons DP; Hyrich KL;
Ann Rheum Dis; 2012 Jun; 71(6):869-74. PubMed ID: 22241900
[TBL] [Abstract][Full Text] [Related]
15. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study.
Kim SC; Pawar A; Desai RJ; Solomon DH; Gale S; Bao M; Sarsour K; Schneeweiss S
Semin Arthritis Rheum; 2019 Oct; 49(2):222-228. PubMed ID: 30967248
[TBL] [Abstract][Full Text] [Related]
16. Brief Report: Intensification to Triple Therapy After Treatment With Nonbiologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States From 2009 to 2014.
Sparks JA; Krumme AA; Shrank WH; Matlin OS; Brill G; Pezalla EJ; Choudhry NK; Solomon DH
Arthritis Rheumatol; 2016 Jul; 68(7):1588-95. PubMed ID: 26866506
[TBL] [Abstract][Full Text] [Related]
17. Risks of different skin tumour combinations after a first melanoma, squamous cell carcinoma and basal cell carcinoma in Dutch population-based cohorts: 1989-2009.
van der Leest RJT; Hollestein LM; Liu L; Nijsten T; de Vries E
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):382-389. PubMed ID: 28898461
[TBL] [Abstract][Full Text] [Related]
18. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
[TBL] [Abstract][Full Text] [Related]
19. An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors.
van Lümig PP; Menting SP; van den Reek JM; Spuls PI; van Riel PL; van de Kerkhof PC; Fransen J; Kievit W; de Jong EM
J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):752-60. PubMed ID: 25229823
[TBL] [Abstract][Full Text] [Related]
20. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.
Huss V; Bower H; Hellgren K; Frisell T; Askling J; ;
Ann Rheum Dis; 2023 Jul; 82(7):911-919. PubMed ID: 36868796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
